返回
GT Biopharma Inc（GTBP）價格
GTBP 股價走勢圖
GTBP 收益
GT Biopharma Inc
$0.72
-2.74%
$-0.02
收盤價：Jan 20, 16:00:00 GMT-5
$0.72
-0.73%
$0
盤後：Jan 20, 20:00:00 GMT-5
關鍵數據
前收市價
$0.7458
開盤價
$0.75
當日範圍
$0.7157 - $0.75
52週區間
$0.54 - $3.85
交易量
801.1K
平均成交量
1.3M
每股盈餘 (TTM)
-5.70
股息收益率
--
市值
$7.6M
什麼是 GTBP？
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in San Francisco, California and currently employs 1 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The firm also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.